טוען...
Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil
A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy. Treprostinil is a synthetic prostacyclin analogue that is currently approved for inhalation administration to patients with pulmonary arterial hyp...
שמור ב:
| הוצא לאור ב: | Pulm Circ |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7682229/ https://ncbi.nlm.nih.gov/pubmed/33282202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894020971509 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|